Publications for Dr. Madhukar Trivedi

Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression

Medication Augmentation after the Failure of SSRIs for Depression

Treatment of Adolescent Depression: Comparison of Psychiatric and Pediatric Settings at an Academic Medical Center Using the VitalSign6 Application.

Characterizing Measurement-Based Care in the Texas Youth Depression and Suicide Research Network (TX-YDSRN).

Predictors of response and remission in patients with treatment-resistant depression: A post hoc pooled analysis of two acute trials of esketamine nasal spray.

Psychometric properties of Concise Associated Symptom Tracking (CAST) scale in youths and young adults: Findings from the Texas youth depression and suicide research network (TX-YDSRN).

Psychometric evaluation of the 9-item Concise Health Risk Tracking - Self-Report (CHRT-SR9) (a measure of suicidal risk) in adolescent psychiatric outpatients in the Texas Youth Depression and Suicide Research Network (TX-YDSRN).

A gender-based secondary analysis of the ADAPT-2 combination naltrexone and bupropion treatment for methamphetamine use disorder trial.

The impact of age on antidepressant response: A mega-analysis of individuals with major depressive disorder.

Temporal multi-step predictive modeling of remission in major depressive disorder using early stage treatment data; STAR*D based machine learning approach.

Examining a Resilience Mental Health App in Adolescents: Acceptability and Feasibility Study.

Predicting suicidal events: A comparison of the Concise Health Risk Tracking Self-Report (CHRT-SR) and the Columbia Suicide Severity Rating Scale (C-SSRS).

Intranasal esketamine effectively treats treatment-resistant depression in adults regardless of baseline irritability.

AI-based dimensional neuroimaging system for characterizing heterogeneity in brain structure and function in major depressive disorder: COORDINATE-MDD consortium design and rationale.

Naltrexone plus bupropion reduces cigarette smoking in individuals with methamphetamine use disorder: A secondary analysis from the CTN ADAPT-2 trial.

Data driven clusters derived from resting state functional connectivity: Findings from the EMBARC study.

Considering depression as a secondary outcome in the optimization of physical activity interventions for breast cancer survivors in the PACES trial: a factorial randomized controlled trial.

Correction: Depression education fotonovela for engagement of Hispanic patients in treatment: a randomized clinical trial.

Leveraging the microbiome to understand clinical heterogeneity in depression: findings from the T-RAD study.

Effects of Mental Illness Exposure From Parents and Friends on Adolescent Mental Health and Well-Being

Reward Behavior Disengagement, a Neuroeconomic Model-Based Objective Measure of Reward Pathology in Depression: Findings from the EMBARC Trial

The Quick Inventory of Depressive Symptomatology, Adolescent Version (QIDS-A17): A Psychometric Evaluation

The 9-item Concise Health Risk Tracking – Self-Report (CHRT-SR9) measure of suicidal risk: Performance in adult primary care patients

Accelerated Brain Aging in Adults with Major Depressive Disorder Predicts Poorer Outcome with Sertraline: Findings from the EMBARC Study.

BLENDS: Augmentation of Functional Magnetic Resonance Images for Machine Learning using Anatomically Constrained Warping.

Accelerated brain aging in individuals with diabetes: Association with poor glycemic control and increased all-cause mortality.

The Concise Health Risk Tracking - Self-Report (CHRT-SR)-A measure of suicidal risk: Performance in adolescent outpatients.

Treatment efficacy and effectiveness in adults with major depressive disorder and childhood trauma history: a systematic review and meta-analysis.

Immune characterization of suicidal behavior in female adolescents.

Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study.

Socioeconomic Predictors of Treatment Outcomes Among Adults With Major Depressive Disorder.

Neural substrates of emotional conflict with anxiety in major depressive disorder: Findings from the Establishing Moderators and biosignatures of Antidepressant Response in Clinical Care (EMBARC) randomized controlled trial.

Multi-Omics Characterization of Early- and Adult-Onset Major Depressive Disorder.

Evidence for machine learning guided early prediction of acute outcomes in the treatment of depressed children and adolescents with antidepressants.

Pitfalls and Recommended Strategies and Metrics for Suppressing Motion Artifacts in Functional MRI.

Alterations in resting-state functional activity and connectivity for major depressive disorder appetite and weight disturbance phenotypes.

Montgomery-Asberg Depression Rating Scale factors in treatment-resistant depression at onset of treatment: Derivation, replication, and change over time during treatment with esketamine.

A Characterization of the Clinical Global Impression Scale Thresholds in the Treatment of Adolescent Depression Across Multiple Rating Scales.

Toward a Definition of "No Meaningful Benefit" From Antidepressant Treatment: An Equipercentile Analysis With Cross-Trial Validation Across Multiple Rating Scales.

Moderation of buprenorphine therapy for cocaine dependence efficacy by variation of the Prodynorphin gene.

Dynamic Resting-State Network Biomarkers of Antidepressant Treatment Response.

Experiencing bullying's impact on adolescent depression and anxiety: Mediating role of adolescent resilience.

Time for united action on depression: a Lancet-World Psychiatric Association Commission.

Fibroblast growth factor 21 (FGF21) is increased in MDD and interacts with body mass index (BMI) to affect depression trajectory.

Psychometric and Clinical Evaluation of the Clinician (VQIDS-C5) and Self-Report (VQIDS-SR5) Versions of the Very Quick Inventory of Depressive Symptoms.

Accelerated Brain Aging in Major Depressive Disorder Predicts Poorer Treatment Outcomes with Sertraline: Findings From the EMBARC Study

Accelerated Brain Aging is Independently Associated With Increased Likelihood of All-Cause Mortality: Findings From the Second Wave of Dallas Heart Study (DHS-2)

Gut Dysbiosis and Accelerated Brain Aging: Findings From the Texas Resilience Against Depression (T-RAD) Study

Network science approach elucidates integrative genomic-metabolomic signature of antidepressant response and lifetime history of attempted suicide in adults with major depressive disorder.

Circulating microRNA associated with future relapse status in major depressive disorder.

Patterns of Pretreatment Reward Task Brain Activation Predict Individual Antidepressant Response: Key Results From the EMBARC Randomized Clinical Trial.

Identifying novel mechanisms and treatment targets for irritability and aggression in psychiatric disorders.

Dysregulation of mitochondrial dynamics, mitophagy and apoptosis in major depressive disorder: Does inflammation play a role?

Psychometric properties of the Generalized Anxiety Disorder 7-item scale in youth: Screening in a primary care sample.

Corrigendum to 'Two Trajectories of Depressive Symptom Reduction Throughout Behavioral Activation Teletherapy Among Underserved, Ethnically Diverse, Primary Care Patients: A VitalSign6 Report'. [Behav. Therapy 51 (2020) 958-971].

A primary care first (PCP-first) model to screen and treat depression: A VitalSign6 report from a second cohort of 32,106 patients.

Impact of childhood maltreatment on outcomes of antidepressant medication in chronic and/or recurrent depression.

Electronic Mental Health Screening in a Pediatric Heart Failure and Transplant Clinic.

Psychometric Evaluation of the Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire in a General Youth Population.

Smoking status links habenular volume to glycated hemoglobin: Findings from the Human Connectome Project-Young Adult.

The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study.

The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder.

Impact of the COVID-19 pandemic on adults with current and prior depression: initial findings from the longitudinal Texas RAD study.

Creation of an algorithm for clinical decision support for treatment of opioid use disorder with buprenorphine in primary care.

Preliminary Evidence for Sociotropy and Autonomy in Relation to Antidepressant Treatment Outcome.

Depression education fotonovela for engagement of Hispanic patients in treatment: a randomized clinical trial.

Dysfunction of default mode network is associated with active suicidal ideation in youths and young adults with depression: Findings from the T-RAD study.

Suicidal Ideation and Depression Among Adolescent and Young Adult Cancer Patients.

Comparison of inflammatory markers as moderators of depression outcomes: A CO-MED study.

The effectiveness of enhanced evidence-based care for depressive disorders: a meta-analysis of randomized controlled trials.

Multi-omics driven predictions of response to acute phase combination antidepressant therapy: a machine learning approach with cross-trial replication.

Irritability as an independent predictor of concurrent and future suicidal ideation in adults with stimulant use disorder: Findings from the STRIDE study.

Prediction of short-term antidepressant response using probabilistic graphical models with replication across multiple drugs and treatment settings.

2020 Articles of Import and Impact.

Clinically Significant Changes in the 17- and 6-Item Hamilton Rating Scales for Depression: A STAR*D Report.

Functional Neuroimaging Moderators of Improvement in Irritability With Antidepressants vs. Placebo in Adults With Major Depressive Disorder: Findings From the EMBARC Study

Research priorities for expanding access to methadone treatment for opioid use disorder in the United States: A National Institute on Drug Abuse Center for Clinical Trials Network Task Force report.

Brain Ventricle Morphology as Predictor of Treatment-Response- Findings From the EMBARC-Study

Moderators of treatment response to exercise in participants with stimulant use disorder: Exploratory results from the Stimulant Reduction using Dosed Exercise (STRIDE)CTN-0037 study

School Personnel and Parents? Concerns Related to COVID-19 Pandemic?s Impact Related to Schools

Neurocircuit Mechanisms of Active Suicidal Ideation in Youths and Young Adults: Findings From the T-Rad Study

Association Between Habenular Volume and Hemoglobin A1c in Young Adults Differs on the Basis of Smoking Status: Findings From the Human Connectome Project

Functional Neuroimaging Moderators of Improvement in Irritability With Antidepressants vs. Placebo in Adults With Major Depressive Disorder: Findings From the EMBARC Study

Addressing adherence to antidepressant treatment for depression.

Identification of psychiatric disorder subtypes from functional connectivity patterns in resting-state electroencephalography.

Clinically Meaningful Changes on Depressive Symptom Measures and Patient-Reported Outcomes in Patients with Treatment-Resistant Depression.

Exploration of baseline and early changes in neurocognitive characteristics as predictors of treatment response to bupropion, sertraline, and placebo in the EMBARC clinical trial.

Sex-specific differences in the association between body mass index and brain aging in young adults: Findings from the human connectome project.

Harmonized Outcome Measures for Use in Depression Patient Registries and Clinical Practice.

Recognizing Inadequate Response in Patients With Major Depressive Disorder.

Anger attacks are associated with persistently elevated irritability in MDD: findings from the EMBARC study.

Identifying and responding to trial implementation challenges during multisite clinical trials.

Dorsolateral Prefrontal Cortex and Subcallosal Cingulate Connectivity Show Preferential Antidepressant Response in Major Depressive Disorder.

Anatomically-Informed Data Augmentation for Functional MRI with Applications to Deep Learning.

Differential response to SSRI versus Placebo and distinct neural signatures among data-driven subgroups of patients with major depressive disorder.

Reply to: EEG-based model and antidepressant response.

A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough?

Effect of Adjunctive Pimavanserin on Sleep/Wakefulness in Patients With Major Depressive Disorder: Secondary Analysis From CLARITY.

Profiles of depression in a treatment-seeking Hispanic population: Psychometric properties of the Patient Health Questionnaire-9.

Improvement of sexual functioning during treatment of MDD with adjunctive pimavanserin: A secondary analysis.

Dissecting the impact of depression on decision-making.

The Adolescent Resilience Questionnaire: Validation of a Shortened Version in U.S. Youths.

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Major Depressive Disorder and an Inadequate Response to Therapy (CLARITY).

Effect of Intrinsic Patterns of Functional Brain Connectivity in Moderating Antidepressant Treatment Response in Major Depression.

Examining raphe-amygdala structural connectivity as a biological predictor of SSRI response.

Culturally adapted depression education and engagement in treatment among Hispanics in primary care: outcomes from a pilot feasibility study.

Dysfunctional adaptive immune response in adolescents and young adults with suicide behavior.

Predicting Response to the Antidepressant Bupropion using Pretreatment fMRI.

VitalSign6: A Primary Care First (PCP-First) Model for Universal Screening and Measurement-Based Care for Depression.

Acute and long-term cannabis use among stimulant users: Results from CTN-0037 Stimulant Reduction Intervention using Dosed Exercise (STRIDE) Randomized Control Trial.

Irritability and Its Clinical Utility in Major Depressive Disorder: Prediction of Individual-Level Acute-Phase Outcomes Using Early Changes in Irritability and Depression Severity.

Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression.

Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression.

Sex differences in the association of baseline c-reactive protein (CRP) and acute-phase treatment outcomes in major depressive disorder: Findings from the EMBARC study.

Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder.

Fatigue in Nondialysis Chronic Kidney Disease: Correlates and Association with Kidney Outcomes.

Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.

When Discontinuing SSRI Antidepressants Is a Challenge: A Response to Letters to the Editor.

A Structured Approach to Detecting and Treating Depression in Primary Care: VitalSign6 Project.

Can targeted metabolomics predict depression recovery? Results from the CO-MED trial.

Toward a very brief quality of life enjoyment and Satisfaction Questionnaire.

The Concise Health Risk Tracking-Self Report: Psychometrics within a placebo-controlled antidepressant trial among depressed outpatients.

Comparative Efficacy of Therapies for Treatment of Depression for Patients Undergoing Maintenance Hemodialysis: A Randomized Clinical Trial.

Inflammation and Response to Sertraline Treatment in Patients With CKD and Major Depression.

Higher S100B Levels Predict Persistently Elevated Anhedonia with Escitalopram Monotherapy Versus Antidepressant Combinations: Findings from CO-MED Trial.

Peripheral cytokine levels and response to antidepressant treatment in depression: a systematic review and meta-analysis.

Discovery and replication of cerebral blood flow differences in major depressive disorder.

Symptoms of Major Depressive Disorder Scale: Performance of a Novel Patient-Reported Symptom Measure.

Cerebral Blood Perfusion Predicts Response to Sertraline versus Placebo for Major Depressive Disorder in the EMBARC Trial.

Sensitivity of derived clinical biomarkers to rs-fMRI preprocessing software versions.

Childhood trauma history is linked to abnormal brain connectivity in major depression.

Prediction of Acute-Phase Treatment Outcomes by Adding a Single-Item Measure of Activity Impairment to Symptom Measurement: Development and Validation of an Interactive Calculator from the STAR*D and CO-MED Trials.

VitalSign6: Screening, Diagnosis, and Treatment of Depression for Adolescents Presenting to Pediatric Primary and Specialty Care Settings.

Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).

Exploring the Association of Sex Differences and Exposure to Maternal Smoking With Low Fetal Growth.

Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.

Anxiety and anhedonia in depression: Associations with neuroticism and cognitive control.

Brain regulation of emotional conflict predicts antidepressant treatment response for depression

The Stimulant Selective Severity Assessment: A replication and exploratory extension of the Cocaine Selective Severity Assessment

E-Behavioral Activation in Primary Care for Depression

Resting EEG Measures of Brain Arousal in a Multisite Study of Major Depression.

The Concise Health Risk Tracking Self-Report (CHRT-SR) assessment of suicidality in depressed outpatients: A psychometric evaluation.

Pharmacogenomics and Biomarkers of Depression.

Association of T and non-T cell cytokines with anhedonia: Role of gender differences.

A psychometric evaluation of the Concise Health Risk Tracking Self-Report (CHRT-SR)- a measure of suicidality-in patients with stimulant use disorder.

Association of Novel ALX4 Gene Polymorphisms with Antidepressant Treatment Response: Findings from the CO-MED Trial.

Association of Midlife Cardiorespiratory Fitness With Incident Depression and Cardiovascular Death After Depression in Later Life.

A Complier Average Causal Effect Analysis of the Stimulant Reduction Intervention using Dosed Exercise Study.

Pretreatment and early-treatment cortical thickness is associated with SSRI treatment response in major depressive disorder.

The Promoting Activity in Cancer Survivors (PACES) trial: a multiphase optimization of strategy approach to increasing physical activity in breast cancer survivors.

Improving the identification and treatment of depression in low-income primary care clinics: a qualitative study of providers in the VitalSign6 program.

Personalized prediction of antidepressant v. placebo response: evidence from the EMBARC study.

Statistical harmonization corrects site effects in functional connectivity measurements from multi-site fMRI data.

Experimental Therapies for Treatment-Resistant Depression: "How do you decide when to go to an unproven or experimental therapy with patients that are treatment-resistant depression?"

Personalized Antidepressant Selection and Pathway to Novel Treatments: Clinical Utility of Targeting Inflammation.

Psychometrics of the Self-Report Concise Associated Symptoms Tracking Scale (CAST-SR): Results From the STRIDE (CTN-0037) Study.

Antisuicidal Effects of Ketamine: A Promising First Step.

Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: Findings from CO-MED trial.

Pretreatment Rostral Anterior Cingulate Cortex Connectivity With Salience Network Predicts Depression Recovery: Findings From the EMBARC Randomized Clinical Trial.

When Discontinuing SSRI Antidepressants Is a Challenge: Management Tips.

Adiponectin Moderates Antidepressant Treatment Outcome in the Combining Medications to Enhance Depression Outcomes Randomized Clinical Trial.

Development and evaluation of a multimodal marker of major depressive disorder.

Do baseline sub-threshold hypomanic symptoms affect acute-phase antidepressant outcome in outpatients with major depressive disorder? Preliminary findings from the randomized CO-MED trial.

A Novel Strategy to Identify Placebo Responders: Prediction Index of Clinical and Biological Markers in the EMBARC Trial.

Pretreatment Rostral Anterior Cingulate Cortex Theta Activity in Relation to Symptom Improvement in Depression: A Randomized Clinical Trial.

Characterizing anxiety subtypes and the relationship to behavioral phenotyping in major depression: Results from the EMBARC study.

Psychopharmacological Treatment in the RAISE-ETP Study: Outcomes of a Manual and Computer Decision Support System Based Intervention.

Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD).

Test-retest reliability of cerebral blood flow in healthy individuals using arterial spin labeling: Findings from the EMBARC study.

Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement.

Efficacy of a Behavioral Activation Teletherapy Intervention to Treat Depression and Anxiety in Primary Care VitalSign6 Program.

Harmonization of cortical thickness measurements across scanners and sites.

Immune-based strategies for mood disorders: facts and challenges.

Worsening Anxiety, Irritability, Insomnia, or Panic Predicts Poorer Antidepressant Treatment Outcomes: Clinical Utility and Validation of the Concise Associated Symptom Tracking (CAST) Scale.

Racial and ethnic differences in treatment outcomes among adults with stimulant use disorders after a dosed exercise intervention.

Proteomics profiling reveals inflammatory biomarkers of antidepressant treatment response: Findings from the CO-MED trial.

A pilot program for implementing mental health screening, assessment, and navigation in a community-based cancer center.

Toward a very brief self-report to assess the core symptoms of depression (VQIDS-SR5 ).

Neuroticism and Individual Differences in Neural Function in Unmedicated Major Depression: Findings from the EMBARC Study.

Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder.

Statistical Analysis Plan for Stage 1 EMBARC (Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care) Study.

Platelet-Derived Growth Factor as an Antidepressant Treatment Selection Biomarker: Higher Levels Selectively Predict Better Outcomes with Bupropion-SSRI Combination.

Pilot investigation into the sickness response to influenza vaccination in adults: Effect of depression and anxiety.

Cardiorespiratory fitness and body composition of stimulant users: A baseline analysis of the STRIDE cohort.

Trajectories of suicidal ideation over 6 months among 482 outpatients with bipolar disorder.

Interleukin 17 selectively predicts better outcomes with bupropion-SSRI combination: Novel T cell biomarker for antidepressant medication selection.

Evaluation of the benefits of exercise on cognition in major depressive disorder.

Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks.

Prediction of treatment outcomes to exercise in patients with nonremitted major depressive disorder.

Side Effects to Antidepressant Treatment in Patients With Depression and Comorbid Panic Disorder.

A comparison of structural connectivity in anxious depression versus non-anxious depression.

Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial.

Reevaluating the Efficacy and Predictability of Antidepressant Treatments: A Symptom Clustering Approach.

Randomized Controlled Trial Comparing Exercise to Health Education for Stimulant Use Disorder: Results From the CTN-0037 STimulant Reduction Intervention Using Dosed Exercise (STRIDE) Study.

Exercise is an effective treatment for positive valence symptoms in major depression.

Measurement, Education and Tracking in Integrated Care (METRIC): use of a culturally adapted education tool versus standard education to increase engagement in depression treatment among Hispanic patients: study protocol for a randomized control trial.

Effects of depression, metabolic syndrome, and cardiorespiratory fitness on mortality: results from the Cooper Center Longitudinal Study.

Is C-reactive protein ready for prime time in the selection of antidepressant medications?

Psychosocial relationship status and quality as predictors of exercise intervention adherence and substance use outcomes: Results from the STRIDE (CTN-0037) study.

Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence: The CAST Randomized Clinical Trial.

Cortical thickness is not associated with current depression in a clinical treatment study.

Demonstrating test-retest reliability of electrophysiological measures for healthy adults in a multisite study of biomarkers of antidepressant treatment response.

Accurately identifying patients who are excellent candidates or unsuitable for a medication: a novel approach.

Daily activity level improvement with antidepressant medications predicts long-term clinical outcomes in outpatients with major depressive disorder.

Harmonization of cortical thickness measurements across scanners and sites

Performance of depression rating scales in patients with chronic kidney disease: an item response theory-based analysis.

Demographic and clinical characteristics of current comorbid psychiatric disorders in a randomized clinical trial for adults with stimulant use disorders.

Neurospora sp. SR8, a novel phosphate solubiliser from rhizosphere soil of Sorghum in Kachchh, Gujarat, India.

Death by Insulin: Management of Self-Harm and Suicide in Diabetes Management.

Right patient, right treatment, right time: biosignatures and precision medicine in depression.

IMPROVEMENTS IN PSYCHOSOCIAL FUNCTIONING AND HEALTH-RELATED QUALITY OF LIFE FOLLOWING EXERCISE AUGMENTATION IN PATIENTS WITH TREATMENT RESPONSE BUT NONREMITTED MAJOR DEPRESSIVE DISORDER: RESULTS FROM THE TREAD STUDY.

Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design.

A tool to predict suicidal ideation and behavior in bipolar disorder: The Concise Health Risk Tracking Self-Report.

Early normalization of Quality of Life predicts later remission in depression: Findings from the CO-MED trial.

Cross-trial prediction of treatment outcome in depression: a machine learning approach.

Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial.

Dose Response for SSRIs.

Understanding the Impact of Treatment on the Dimensions of Childhood Depression.

Atypical depressive symptoms as a predictor of treatment response to exercise in Major Depressive Disorder.

Early Improvement in Work Productivity Predicts Future Clinical Course in Depressed Outpatients: Findings From the CO-MED Trial.

Affect Following First Exercise Session as a Predictor of Treatment Response in Depression.

An ounce of prevention: A pre-randomization protocol to improve retention in substance use disorder clinical trials.

Baseline medical comorbidities in adults randomized in the STRIDE trial for psychostimulant use disorders.

Depression Screening and Education: Options to Reduce Barriers to Treatment (DESEO): protocol for an educational intervention study.

Prognostic Utility of a Self-Reported Depression Questionnaire versus Clinician-Based Assessment on Renal Outcomes.

Early Improvement in Psychosocial Function Predicts Longer-Term Symptomatic Remission in Depressed Patients.

A COMPREHENSIVE EXAMINATION OF WHITE MATTER TRACTS AND CONNECTOMETRY IN MAJOR DEPRESSIVE DISORDER.

A clinical measure of suicidal ideation, suicidal behavior, and associated symptoms in bipolar disorder: Psychometric properties of the Concise Health Risk Tracking Self-Report (CHRT-SR).

Rationale and design of A Trial of Sertraline vs. Cognitive Behavioral Therapy for End-stage Renal Disease Patients with Depression (ASCEND).

A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder.

A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder.

Test-retest reliability of freesurfer measurements within and between sites: Effects of visual approval process.

A computational analysis of flanker interference in depression.

Evaluation of anhedonia with the Snaith-Hamilton Pleasure Scale (SHAPS) in adult outpatients with major depressive disorder.

On the invariance of the Stimulant Craving Questionnaire (STCQ) across cocaine and methamphetamine users.

Neural Correlates of Three Promising Endophenotypes of Depression: Evidence from the EMBARC Study.

Moderation of the Relationship Between Reward Expectancy and Prediction Error-Related Ventral Striatal Reactivity by Anhedonia in Unmedicated Major Depressive Disorder: Findings From the EMBARC Study.

Comorbidities and Race/Ethnicity Among Adults with Stimulant Use Disorders in Residential Treatment.

A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD.

Men and women from the STRIDE clinical trial: An assessment of stimulant abstinence symptom severity at residential treatment entry.

Identifying predictors, moderators, and mediators of antidepressant response in major depressive disorder: neuroimaging approaches.

Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper: a discrete survival and growth mixture model.

Prevalence and impact of obsessive-compulsive symptoms in depression: a STAR*D report.

IL-1? and BDNF are associated with improvement in hypersomnia but not insomnia following exercise in major depressive disorder.

Accounting for Dynamic Fluctuations across Time when Examining fMRI Test-Retest Reliability: Analysis of a Reward Paradigm in the EMBARC Study.

Opioid addiction screening tools for patients with chronic noncancer pain.

Dose-dependent changes in cognitive function with exercise augmentation for major depression: Results from the TREAD study.

Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: A CO-MED report.

Preliminary evidence that early reduction in p11 levels in natural killer cells and monocytes predicts the likelihood of antidepressant response to chronic citalopram.

Adherence to antidepressant combinations and monotherapy for major depressive disorder: a CO-MED report of measurement-based care.

A Health Education Intervention as the Control Condition in the CTN-0037 STRIDE multi-site exercise trial: Rationale and Description.

Brief, unidimensional melancholia rating scales are highly sensitive to the effect of citalopram and may have biological validity: Implications for the Research Domain Criteria (RDoC).

Cognitive dysfunction in unipolar depression: implications for treatment.

Influence of sex and menopausal status on response, remission, and recurrence in patients with recurrent major depressive disorder treated with venlafaxine extended release or fluoxetine: analysis of data from the prevent study.

ABCB1 (MDR1) predicts remission on P-gp substrates in chronic depression.

Inflammation, obesity, and metabolic syndrome in depression: analysis of the 2009-2010 National Health and Nutrition Examination Survey (NHANES).

Depressive Symptoms and Associated Clinical Characteristics in Outpatients Seeking Community-based Treatment for Alcohol and Drug Problems.

Self-rated measure of pain frequency, intensity, and burden: Psychometric properties of a new instrument for the assessment of pain.

Childhood Depression Subscales Using Repeated Sessions on Children's Depression Rating Scale - Revised (CDRS-R) Scores.

Research staff training in a multisite randomized clinical trial: Methods and recommendations from the Stimulant Reduction Intervention using Dosed Exercise (STRIDE) trial.

Does duloxetine improve cognitive function independently of its antidepressant effect in patients with major depressive disorder and subjective reports of cognitive dysfunction?

Relationship between obesity and depression: characteristics and treatment outcomes with antidepressant medication.

Brief report: depression and history of suicide attempts in adults with new-onset Type 2 Diabetes.

Evaluation of the effects of extended release quetiapine fumarate monotherapy on sleep disturbance in patients with major depressive disorder: a pooled analysis of four randomized acute studies.

Evidence-based recommendations for the prescription of exercise for major depressive disorder.

Quetiapine XR monotherapy in major depressive disorder: a pooled analysis to assess the influence of baseline severity on efficacy.

The Clinical Relevance of Self-Reported Premenstrual Worsening of Depressive Symptoms in the Management of Depressed Outpatients: A STAR*D Report.

Increase in work productivity of depressed individuals with improvement in depressive symptom severity.

Modeling predictors, moderators and mediators of treatment outcome and resistance in depression.

Evaluating and monitoring treatment response in depression using measurement-based assessment and rating scales.

Response to Stanton, Reaburn, and Rosenbaum.

Sustaining practice change one year after completion of the national depression management leadership initiative.

Rationale and design of the Chronic Kidney Disease Antidepressant Sertraline Trial (CAST).

Quantitative electroencephalogram biomarkers for predicting likelihood and speed of achieving sustained remission in major depression: a report from the biomarkers for rapid identification of treatment effectiveness in major depression (BRITE-MD) trial.

Clinical and sociodemographic characteristics associated with suicidal ideation in depressed outpatients.

Do Menopausal Status and Use of Hormone Therapy Affect Antidepressant Treatment Response? Findings from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study.

Lisdexamfetamine Dimesylate Augmentation in Adults With Persistent Executive Dysfunction After Partial or Full Remission of Major Depressive Disorder.

A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.

Using measurement-based care with patient involvement to improve outcomes in depression.

Phosphate solubilizing microbes: sustainable approach for managing phosphorus deficiency in agricultural soils.

Cognitive and Psychosocial Improvements Following Aripiprazole Augmentation of SSRI Antidepressant Therapy in Treatment Refractory Depression: A Pilot Study

Testing the efficacy of quercetin in mitigating bisphenol A toxicity in liver and kidney of mice.

Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth.

Decline in cardiorespiratory fitness and odds of incident depression.

Correlates and outcomes of depressed out-patients with greater and fewer anxious symptoms: a CO-MED report.

Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: results from the CO-MED trial.

Is prior course of illness relevant to acute or longer-term outcomes in depressed out-patients? A STAR*D report.

The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations.

Exercise and mental illness: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC).

Depression treatment in patients with general medical conditions: results from the CO-MED trial.

Effects of heart disease on depression treatment: results from the COMED study.

Rationale and methods for site selection for a trial using a novel intervention to treat stimulant abuse.

Effect of concurrent substance use disorder on the effectiveness of single and combination antidepressant medications for the treatment of major depression: an exploratory analysis of a single-blind randomized trial.

What are the clinical implications of new onset or worsening anxiety during the first two weeks of SSRI treatment for depression?

Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED Trial Report.

Neural correlates of successful response inhibition in unmedicated patients with late-life depression.

STimulant Reduction Intervention using Dosed Exercise (STRIDE) - Description of the Exercise Intervention and Behavioral Program to Ensure Adherence.

Does exercise improve self-reported sleep quality in non-remitted major depressive disorder?

Pro-inflammatory cytokines as predictors of antidepressant effects of exercise in major depressive disorder.

Feasible evidence-based strategies to manage depression in primary care.

Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial.

Biomarkers and the Future of Treatment for Depression.

Measurement-Based Care in the Treatment of Clinical Depression

Rationale for Using Exercise in the Treatment of Stimulant Use Disorders.

Power of automated algorithms for combining time-line follow-back and urine drug screening test results in stimulant-abuse clinical trials.

Determining the primary endpoint for a stimulant abuse trial: lessons learned from STRIDE (CTN 0037).

Performance improvement CME: algorithms and EMRs in depression.

Moderators of antidepressant response in major depression.

Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study.

Changes in depressive symptoms and social functioning in the sequenced treatment alternatives to relieve depression study.

Effects of race and ethnicity on depression treatment outcomes: the CO-MED trial.

Prospective trial of equine-assisted activities in autism spectrum disorder.

Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: A CO-MED report.

Exercise as an augmentation treatment for nonremitted major depressive disorder: a randomized, parallel dose comparison.

Antenatal depression: a rationale for studying exercise.

Crisis of confidence: antidepressant risk versus benefit.

Fractional anisotropy changes after several weeks of daily left high-frequency repetitive transcranial magnetic stimulation of the prefrontal cortex to treat major depression.

Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: results from the PREVENT study.

Effects of serum Brain Derived Neurotrophic Factor on exercise augmentation treatment of depression.

Children of depressed mothers 1 year after remission of maternal depression: findings from the STAR*D-Child study.

Concise associated symptoms tracking scale: a brief self-report and clinician rating of symptoms associated with suicidality.

Concise Health Risk Tracking scale: a brief self-report and clinician rating of suicidal risk.

Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and Long-Term Outcomes of a Single-Blind Randomized Study.

Using moderator-based algorithms and electronic medical records to achieve optimal outcomes in depression.

Concordance between clinician and patient ratings as predictors of response, remission, and recurrence in major depressive disorder.

Measurement-based care in psychiatric practice: a policy framework for implementation.

The current crisis of confidence in antidepressants.

The relationship between adverse events during selective serotonin reuptake inhibitor treatment for major depressive disorder and nonremission in the suicide assessment methodology study.

Measurement-based care for unipolar depression.

Assessing anxious features in depressed outpatients.

Using algorithms and computerized decision support systems to treat major depression.

Depression outcomes in psychiatric clinical practice: using a self-rated measure of depression severity.

Factor structure and dimensionality of the two depression scales in STAR*D using level 1 datasets.

Association between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder.

Analysis of suicidality in pooled data from 2 double-blind, placebo-controlled aripiprazole adjunctive therapy trials in major depressive disorder.

Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication.

Challenges and algorithm-guided treatment in major depressive disorder.

Functional connectivity of brain structures correlates with treatment outcome in major depressive disorder.

Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder.

Remission with venlafaxine extended release or selective serotonin reuptake inhibitors in depressed patients: a randomized, open-label study.

Stimulant reduction intervention using dosed exercise (STRIDE) - CTN 0037: study protocol for a randomized controlled trial.

Diagnostic utility of the Quick Inventory of Depressive Symptomatology (QIDS-C16 and QIDS-SR16) in the elderly.

Depressive symptoms and metabolic syndrome in preventive healthcare: the Cooper Center longitudinal study.

Psychometric evaluation of the Snaith-Hamilton pleasure scale in adult outpatients with major depressive disorder.

Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release.

Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial.

Effect of 11 September 2001 terrorist attacks in the USA on suicide in areas surrounding the crash sites.

Association between major depressive episodes in patients with chronic kidney disease and initiation of dialysis, hospitalization, or death.

Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes.

Dyadic discord at baseline is associated with lack of remission in the acute treatment of chronic depression.

Indicators of pretreatment suicidal ideation in adults with major depressive disorder.

Insomnia in patients with depression: a STAR*D report.

Complementary and alternative medicine in major depressive disorder: the American Psychiatric Association Task Force report.

Early adverse events and attrition in selective serotonin reuptake inhibitor treatment: a suicide assessment methodology study report.

Anticipated Benefits of Care (ABC): psychometrics and predictive value in psychiatric disorders.

A Comparison of the QIDS-C16, QIDS-SR16, and the MADRS in an Adult Outpatient Clinical Sample.

The influence of menopause status and postmenopausal use of hormone therapy on presentation of major depression in women.

The impact of diabetes on depression treatment outcomes.

Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report.

Health-related quality of life in depression: a STAR*D report.

Do atypical features affect outcome in depressed outpatients treated with citalopram?

Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced Treatment Alternatives to Relieve Depression) report.

Psychometric properties of the Quick Inventory of Depressive Symptomatology in adolescents.

Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a consensus statement.

Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a brief report.

Defining and measuring functional recovery from depression.

Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response.

Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies.

Treating partial responders to antidepressant treatment.

Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: results of the BRITE-MD study.

Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder.

Factors associated with concomitant psychotropic drug use in the treatment of major depression: a STAR*D Report.

Release bias in accessing medical records in clinical trials: a STAR*D report.

Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalopram in the STAR*D study.

What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression.

Cognitive behavioral analysis system of psychotherapy and brief supportive psychotherapy for augmentation of antidepressant nonresponse in chronic depression: the REVAMP Trial.

Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report.

Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder.

Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning.

What predicts attrition in second step medication treatments for depression?: a STAR*D Report.

Abnormal brain response to cholinergic challenge in chronic encephalopathy from the 1991 Gulf War.

Voice response system to measure healthcare costs: a STAR*D report.

An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression.

Predictors of attrition during one year of depression treatment: a roadmap to personalized intervention.

A psychometric evaluation of the clinician-rated Quick Inventory of Depressive Symptomatology (QIDS-C16) in patients with bipolar disorder.

Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms.

Telephone-based assessments to minimize missing data in longitudinal depression trials: a project IMPACTS study report.

Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome.

Treating depression to full remission.

Family history of depression and therapeutic outcome: findings from STAR*D.

Sex differences in response to citalopram: a STAR*D report.

DATE: Depressed adolescents treated with exercise: Study rationale and design for a pilot study.

Exercise in the treatment of depression.

STAR*D: revising conventional wisdom.

Irritability is associated with anxiety and greater severity, but not bipolar spectrum features, in major depressive disorder.

Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.

Income and attrition in the treatment of depression: a STAR*D report.

Early adversity in chronic depression: clinical correlates and response to pharmacotherapy.

Sociodemographic, clinical, and treatment characteristics associated with worsened depression during treatment with citalopram: results of the NIMH STAR(*)D trial.

Diurnal mood variation in outpatients with major depressive disorder.

Barriers to implementation of a computerized decision support system for depression: an observational report on lessons learned in "real world" clinical settings.

The impact of nonclinical factors on care use for patients with depression: a STAR*D report.

Tools and strategies for ongoing assessment of depression: a measurement-based approach to remission.

Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163).

Do Depressed Patients With Diabetes Experience More Side Effects When Treated With CitalopramThan Their Counterparts Without Diabetes? A STAR*D Study.

A computerized decision support system for depression in primary care.

Assessing Rates and Predictors of Tachyphylaxis During the Prevention of Recurrent Episodes of Depression With Venlafaxine ER for Two Years (PREVENT) Study.

Identifying risk for attrition during treatment for depression.

Effectiveness study of venlafaxine-XR combined with aripiprazole for chronic or recurrent major depressive disorder

Course and Severity of Maternal Depression: Associations with Family Functioning and Child Adjustment.

Children of depressed mothers 1 year after the initiation of maternal treatment: findings from the STAR*D-Child Study.

Chronic forms of major depression are still undertreated in the 21st century: systematic assessment of 801 patients presenting for treatment.

An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder.

Factors predicting reduced antidepressant response: experience with the SNRI duloxetine in patients with major depression.

The effect of pain on outcomes in a trial of duloxetine treatment of major depressive disorder.

Remission of maternal depression: relations to family functioning and youth internalizing and externalizing symptoms.

The history and current state of antidepressant clinical trial design: a call to action for proof-of-concept studies.

Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study.

Sex differences in depression symptoms in treatment-seeking adults: confirmatory analyses from the Sequenced Treatment Alternatives to Relieve Depression study.

Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine.

A comparison of baseline sociodemographic and clinical characteristics between major depressive disorder patients with and without diabetes: a STAR*D report.

Family history of completed suicide and characteristics of major depressive disorder: a STAR*D (sequenced treatment alternatives to relieve depression) study.

Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR*D.

Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report.

Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies.

Faster remission of chronic depression with combined psychotherapy and medication than with each therapy alone.

Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: a meta-analysis of individual patient data from 10 double-blind, randomized clinical trials.

Treatment outcomes for older depressed patients with earlier versus late onset of first depressive episode: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report.

The STAR*D study: treating depression in the real world.

Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression.

Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.

Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report.

Do geographic regions with higher suicide rates also have higher rates of nonfatal intentional self-harm?

Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features.

Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report.

Folate and unipolar depression.

Prenatal depression in women hospitalized for obstetric risk.

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.

Developing a neuropsychiatric functional brain imaging test.

Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studies.

REVAMP - Research Evaluating the Value of Augmenting Medication with Psychotherapy: rationale and design.

Symptom features of postpartum depression: are they distinct?

Treatment strategies to improve and sustain remission in major depressive disorder.

Systematic Use of Patient-Rated Depression Severity Monitoring: Is It Helpful and Feasible in Clinical Psychiatry?

Major depressive disorder and comorbid cardiac disease: is there a depressive subtype with greater cardiovascular morbidity? Results from the STAR*D study.

A psychometric evaluation of the CDRS and MADRS in assessing depressive symptoms in children.

A pilot study of an electronic, adolescent version of the quick inventory of depressive symptomatology.

Diurnal mood variation in outpatients with major depressive disorder: implications for DSM-V from an analysis of the Sequenced Treatment Alternatives to Relieve Depression Study data.

Effect of age at onset on the course of major depressive disorder.

Electronic source materials in clinical research: acceptability and validity of symptom self-rating in major depressive disorder.

Ethnicity/race and outcome in the treatment of depression: results from STAR*D.

Amelioration by black tea of sodium fluoride-induced changes in protein content of cerebral hemisphere, cerebellum and medulla oblongata in brain region of mice.

Acceptability of second-step treatments to depressed outpatients: a STAR*D report.

Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report.

Measurement-based care for refractory depression: a clinical decision support model for clinical research and practice.

Exercise for mood and anxiety disorders.

Major depression symptoms in primary care and psychiatric care settings: a cross-sectional analysis.

Sensory correlations in autism.

Comparison of quality of life measures in a depressed population.

Preadult onset vs. adult onset of major depressive disorder: a replication study.

Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study.

Texas Children's Medication Algorithm Project: update from Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder.

Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression.

Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study.

Clinical differences among depressed patients with and without a history of suicide attempts: findings from the STAR*D trial.

Treating depression complicated by comorbid medical illness or anxiety.

Managing depressive disorders in patients with epilepsy.

Assessing physicians' use of treatment algorithms: Project IMPACTS study design and rationale.

Increased expression of the remodeling- and tumorigenic-associated factor osteopontin in pyramidal neurons of the Alzheimer's disease brain.

The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases.

The STAR*D Project results: a comprehensive review of findings.

Are depressed outpatients with and without a family history of substance use disorder different? A baseline analysis of the STAR*D cohort.

A review of quetiapine in combination with antidepressant therapy in patients with depression.

Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR(*)D measurement-based care.

Remission of maternal depression and child symptoms among single mothers: a STAR*D-Child report.

Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report.

Consensus recommendations for improving adherence, self-management, and outcomes in patients with depression.

The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases.

Pain in depression: STAR*D study findings.

Influences of hormone-based contraception on depressive symptoms in premenopausal women with major depression.

Insured and non-insured depressed outpatients: how do they compare?

Clinical vs. self-report versions of the quick inventory of depressive symptomatology in a public sector sample.

Family history of mood disorder and characteristics of major depressive disorder: a STAR*D (sequenced treatment alternatives to relieve depression) study.

Sulfhydryl-reactive metals in autism.

Clinical features of depression in outpatients with and without co-occurring general medical conditions in STAR*D: confirmatory analysis.

Screening for depression in a diabetic outpatient population.

Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report.

A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report.

The pattern of sensory processing abnormalities in autism.

Use of treatment algorithms for depression.

Implementation of the Texas Medication Algorithm Project patient and family education program.

Report by the ACNP Task Force on response and remission in major depressive disorder.

Making clinicians lives easier: guidance on use of the QIDS self-report in place of the MADRS.

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.

What clinical and symptom features and comorbid disorders characterize outpatients with anxious major depressive disorder: a replication and extension.

Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment.

An empirical analysis of cost outcomes of the Texas Medication Algorithm Project.

Medication augmentation after the failure of SSRIs for depression.

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

Remissions in maternal depression and child psychopathology: a STAR*D-child report.

An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report.

Self-rated global measure of the frequency, intensity, and burden of side effects.

Datapoints: rates of nonfatal intentional self-harm in nine states, 2001.

Prevention of missing data in clinical research studies.

Comparison of self-report and clinician ratings on two inventories of depressive symptomatology.

Substance use disorder comorbidity in major depressive disorder: a confirmatory analysis of the STAR*D cohort.

A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report.

Exercise as an augmentation strategy for treatment of major depression.

Children of currently depressed mothers: a STAR*D ancillary study.

Inverse association between physical inactivity and mental health in men and women.

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

Factors associated with health-related quality of life among outpatients with major depressive disorder: a STAR*D report.

The Montgomery Asberg and the Hamilton ratings of depression: a comparison of measures.

Item Response Analysis of the Inventory of Depressive Symptomatology.

Epidemiology of nonfatal deliberate self-harm in the United States as described in three medical databases.

TREAD: TReatment with Exercise Augmentation for Depression: study rationale and design.

Consensus statement and research needs: the role of dopamine and norepinephrine in depression and antidepressant treatment.

Major depressive disorder: remission of associated symptoms.

Treatment-resistant depression.

Evaluation of Outcomes With Citalopram for Depression Using Measurement-Based Care in STAR*D: Implications for Clinical Practice

Recent Advances in the Treatment of Depression in the Presence of Physical Symptoms

Exercise as an Augmentation Strategy for Treatment of Major Depression.

Use of Treatment Algorithms for Depression

Factors Associated with Health-Related Quality of Life Among Outpatients with Major Depressive Disorder: A STARD Report.

Assessing insomnia severity in depression: comparison of depression rating scales and sleep diaries.

Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not.

Depression and pain: implications for symptomatic presentation and pharmacological treatments.

Self-reported premenstrual exacerbation of depressive symptoms in patients seeking treatment for major depression.

A direct comparison of presenting characteristics of depressed outpatients from primary vs. specialty care settings: preliminary findings from the STAR*D clinical trial.

What moderator characteristics are associated with better prognosis for depression?

Impaired delay and trace eyeblink conditioning performance in major depressive disorder.

Brief psychiatric rating scale expanded version: How do new items affect factor structure?

Comorbid psychiatric disorders in depressed outpatients: demographic and clinical features.

Exercise treatment for depression: efficacy and dose response.

Prevalence and clinical correlates of irritability in major depressive disorder: a preliminary report from the Sequenced Treatment Alternatives to Relieve Depression study.

Self-reported depressive symptom measures: sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients.

Quality improvement methods as applied to a multicenter effectiveness trial--STAR*D.

Response to Zhang et al. (2005): loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron 45, 11-16.

Factors associated with chronic depressive episodes: a preliminary report from the STAR-D project.

Does provider adherence to a treatment guideline change clinical outcomes for patients with bipolar disorder? Results from the Texas Medication Algorithm Project.

Gender differences in depression: findings from the STAR*D study.

Symptom clusters as predictors of late response to antidepressant treatment.

Characteristics of insured and noninsured outpatients with depression in STAR(*)D.

Psychotherapy and medication in the treatment of adult and geriatric depression: which monotherapy or combined treatment?

Reductions in stress and depressive symptoms in mothers of substance-exposed infants, participating in a psychosocial program.

Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.

Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder.

Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D.

Clinical features of depressed outpatients with and without co-occurring general medical conditions in STAR*D.

Suicide risk management for the sequenced treatment alternatives to relieve depression study: applied NIMH guidelines.

Methods of testing feasibility for sequenced treatment alternatives to relieve depression (STAR*D).

Clinicians' adherence to an algorithm for pharmacotherapy of depression in the Texas public mental health sector.

Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project.

One-year clinical outcomes of depressed public sector outpatients: a benchmark for subsequent studies.

The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation.

Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design.

The effectiveness of secretin in the management of autism.

Factors that differentiate early vs. later onset of major depression disorder.

Cognitive-behavioral analysis system of psychotherapy as a maintenance treatment for chronic depression.

A computerized clinical decision support system as a means of implementing depression guidelines.

The link between depression and physical symptoms.

The Texas Medication Algorithm Project (TMAP): Clinical Results for Patients with Major Depressive Disorder

Web-based communications and management of a multi-center clinical trial: the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) project.

The Texas medication algorithm project: clinical results for schizophrenia.

The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression.

Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression.

The effects of psychotherapy, nefazodone, and their combination on subjective assessment of disturbed sleep in chronic depression.

Treatment-resistant depression: new therapies on the horizon.

Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study.

Depression, IV: STAR*D treatment trial for depression.

Catching up on health outcomes: the Texas Medication Algorithm Project.

Texas Medication Algorithm Project, phase 3 (TMAP-3): clinical results for patients with a history of mania.

Texas Medication Algorithm Project, phase 3 (TMAP-3): rationale and study design.

Using treatment algorithms to bring patients to remission.

Remission of depression and the Texas Medication Algorithm Project.

Continuation treatment of chronic depression: a comparison of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination.

The DOSE study: a clinical trial to examine efficacy and dose response of exercise as treatment for depression.

Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination.

Efficacy of porcine secretin in children with autism and pervasive developmental disorder.

Differential effects of nefazodone and cognitive behavioral analysis system of psychotherapy on insomnia associated with chronic forms of major depression.

Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination.

Quantitative EEG amplitude across REM sleep periods in depression: preliminary report.

Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination.

Development and implementation of computerized clinical guidelines: barriers and solutions.

Algorithms in clinical psychiatry: a stepped approach toward the path to recovery.

Optimizing treatment outcomes for patients with depression and generalized anxiety disorder.

Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients?

Strengthening clinical effectiveness trials: equipoise-stratified randomization.

Which depressed patients respond to nefazodone and when?

Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial.

Physical activity dose-response effects on outcomes of depression and anxiety.

Occipital brain perfusion deficits in children with major depressive disorder.

Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline.

Regional cerebral blood flow response to oral amphetamine challenge in healthy volunteers.

Sensitizing clinicians and patients to the social and functional aspects of remission.

Using treatment algorithms for the effective management of treatment-resistant depression.

Algorithm for the treatment of chronic depression.

An ideal trial to test differential onset of antidepressant effect.

Clinical significance of monitoring early symptom change to predict outcome.

Do Bupropion SR and Sertraline Differ in Their Effects on Anxiety in Depressed Patients

Which Depressed Patients Respond to Nefazodone and When?

Computerizing medication algorithms and decision support systems for major psychiatric disorders.

Slow-wave activity in NREM sleep: sex and age effects in depressed outpatients and healthy controls.

A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression.

A comparison of alternative assessments of depressive symptom severity: a pilot study.

Temporal characteristics of delta activity during NREM sleep in depressed outpatients and healthy adults: group and sex effects.

Evaluation of newer treatment interventions for psychotic depression.

High grade, synchronous colon cancers after renal transplantation: were immunosuppressive drugs to blame?

The Texas Children's Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder.

Medication treatment for the severely and persistently mentally ill: the Texas Medication Algorithm Project.

Effects of fluoxetine on the polysomnogram in outpatients with major depression.

A SPECT HMPAO study of regional cerebral blood flow in depressed adolescents and normal controls.

Treatment of depression--newer pharmacotherapies.

The Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder.

Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression.

Anaplastic and sarcomatoid carcinoma of the small intestine: an unusual tumor.

Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression.

Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group.

Mental health care from the public perspective: the Texas Medication Algorithm Project.

A Spect HMPAO Study of Regional Cerebral Bloodflow in Depressed Adolescents and Normal Controls

Treatment of depression--newer pharmacotherapies.

Consensus guidelines in the treatment of major depressive disorder.

Developing treatment algorithms for unipolar depression in Cyberspace: International Psychopharmacology Algorithm Project (IPAP).

Growth hormone response to the GABAB agonist baclofen in major depressive disorder.

Relationship between objective and subjective sleep measures in depressed patients and healthy controls.

The psychopharmacological treatment of nonmajor mood disorders.

Comparison of technetium-99m-HMPAO and xenon-133 measurements of regional cerebral blood flow by SPECT.

The Inventory of Depressive Symptomatology (IDS): psychometric properties.

Functional neuroanatomy of obsessive-compulsive disorder.

Benzodiazepines as antidepressants: does GABA play a role in depression?

MAOIs in the contemporary treatment of depression.

Sex differences in the distribution of EEG frequencies during sleep: unipolar depressed outpatients.

Congestive gastropathy: factors influencing development, endoscopic features, Helicobacter pylori infection, and microvessel changes.

Guidelines for the diagnosis and treatment of depression for primary care physicians. Implications for consultation-liaison psychiatrists.

Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications?

The effects of nefazodone on sleep architecture in depression.

Regional cerebral blood flow alterations in unipolar depression.

The development of clinical practice guidelines for the diagnosis and treatment of depression.

[As others see us].